Treatment and Clinical Outcomes Among SLE Patients in Pregnancy

Objective: To study the risk factors of poor pregnancy outcomes in SLE patients, and evaluate impact of different therapies on the maternal and fetal health. Methods: Our department and Shanghai Gothic Network Technology Co., Ltd. jointly established the chronic disease management of SLE patients during pregnancy and lactation by using Smart System of Disease Management#SSDM#. With this platform#patients in pregnancy can consult with rheumatologists face to face and follow-up regularly.

Follow-up: Consultation and followup will be scheduled every 4 weeks from confirmed pregnancy until delivery.

Inclusion criteria

• Patients diagnosed with systemic lupus erythematosus (SLE) (ACR criteria, 1997);
• Pregnant women aged 20-45 years old;
• Willing to participate in this study, willing to medication and follow-up according to the treatment plan, and sign the informed consent.

Exclusion criteria

• The cause of previous abortion was known:

• Known chromosomal abnormalities in the parent, maternal or embryo.

• Page 3 of 4 [DRAFT] -• Endocrine dysfunction of pregnant women: luteal dysfunction; Polycystic ovarian syndrome; Ovarian premature failure (FSH

≥ 20uu/ L) in follicular stage;

• Hyperprolactinemia thyroid disease; Other hypothalamic pituitary adrenal axis abnormalities in diabetes mellitus.
• Abnormal anatomy of pregnant women: abnormal uterus; Asherman syndrome; The uterine fibrosis of cervical insufficiency is more than 5 cm. Vaginal infection.
• Any known serious heart disease, liver, kidney, blood or endocrine disease.
• Any active infection Active viral hepatitis includes hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV). Active infections include small intestine herpes zoster virus (VZV), human immunodeficiency virus (HIV), syphilis or tuberculosis.
• Allergic to prednisone, hydroxychloroquine, low molecular weight heparin or aspirin.
• The history of the disease is as follows:

• There was a history of peptic ulcer or upper gastrointestinal bleeding in the past.
• The past history of malignant tumor.
• The past history of epilepsy or psychosis.
• Women who disagree or cannot complete the follow-up during pregnancy and after delivery.